- News & Features
This June, CreakyJoints attended the annual conference of the European League Against Rheumatism (EULAR). Researchers, physicians and patient groups gathered in Madrid to share research findings, attend seminars, and work together to improve the lives of patients living with rheumatic diseases.
This year, the Global Healthy Living Foundation and CreakyJoints presented three posters and an abstract highlighting the research activities we have performed in the last year.
CreakyJoints is also delighted to have had an abstract published. It was published in the electronic “Abstract Book”; an Official Supplement to the “Annals of Rheumatic Diseases ARD”; in PDF form on the EULAR website, and will also be shipped by BMJ to all subscribers of ARD as a CD-ROM. It is entitled “Development of Patient Preference Phenotypes for Rheumatoid Arthritis” (Program number AB0370).
The U.S. Food and Drug Administration is currently reviewing Simponi, an intravenous TNF-inhibitor, for psoriatic arthritis and ankylosing spondylitis patients.
Postmenopausal women with osteoporosis who took romosozumab for a year experienced “rapid and large reductions” in risk of fracturing vertebrae.
EULAR report highlights the importance of early intervention in the treatment of people with rheumatic and musculoskeletal diseases.